Spectrum Pharmaceutecals Inc (SPPI)

[Just Jack]

Poziotinib - HANMI Phase II results
Available 8/31
Presentation 9/9
POZIOTINIB RESULTS PRESENTATION (ABSTRACT AVAILABLE ON AUGUST 31ST)

Breast cancer, metastatic
Chair(s) F. André (Villejuif, France)
Session
Type
Proffered Paper session
Details ESMO 2017 Congress, 2017-09-09, 11:00 - 12:30, Madrid Auditorium
One LBA TBC
237O - A phase II trial of pan-HER inhibitor Poziotinib, in patients with
HER2-positive metastatic breast cancer who have received at least two prior
HER2-directed regimens: The results of NOV120101-203 trial.
Y. Park (Seoul, Korea, Republic of)K. Lee (Seoul, Korea, Republic of)J. Sohn (Seoul, Korea, Republic of)
K. Lee (Goyang, Korea, Republic of)K. Jung (Seoul, Korea, Republic of)J. Kim (Seongnam, Korea, Republic of)
K. Lee (Cheongju, Korea, Republic of)J. Ahn (Seoul, Korea, Republic of)T. Kim (Seoul, Korea, Republic of)
G. Kim (Seoul, Korea, Republic of)I. Park (Goyang, Korea, Republic of)S. Kim (Seoul, Korea, Republic of)
S. Kim (Seongnam, Korea, Republic of)H. Han (Cheongju, Korea, Republic of)Y. Im (Seoul, Korea, Republic of)
J. Ahn (Seoul, Korea, Republic of)J. Kim (Goyang, Korea, Republic of)J. Kang (Seoul, Korea, Republic of)
S. Im (Seoul, Korea, Republic of)
Invited Discussant one LBA TBC and 237O
One LBA TBC
One LBA TBC
Invited Discussant two LBAs TBC